Sign In
Buy CBIO
$17.98
+0.98 (+5.73%)
At Close: Jun 03, 2026
Crescent Biopharma to Present at June Investor Conferences
04:15pm, Tuesday, 02'nd Jun 2026
WALTHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing t
Crescent Biopharma Announces Grants of Inducement Awards
04:15pm, Friday, 29'th May 2026
WALTHAM, Mass., May 29, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing th
ASCEND Phase 1/2 global clinical trial evaluating CR-001 in multiple solid tumor types, including NSCLC, gastrointestinal and gynecological cancers in first-line and previously treated patients Multip
Crescent Biopharma Announces Grants of Inducement Awards
04:30pm, Tuesday, 12'th May 2026
WALTHAM, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing th
Crescent Biopharma to Present at May Investor Conferences
07:30am, Wednesday, 06'th May 2026
WALTHAM, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing th
Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights
04:15pm, Wednesday, 29'th Apr 2026
ASCEND Phase 1/2 global clinical trial ongoing, evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treated patients; first ADC combination
Crescent Biopharma Announces Grants of Inducement Awards
04:15pm, Friday, 24'th Apr 2026
WALTHAM, Mass., April 24, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing
Crescent Biopharma Announces Grants of Inducement Awards
04:15pm, Friday, 27'th Mar 2026
WALTHAM, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing
Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives $28.00 Average Target Price from Brokerages
01:31am, Friday, 27'th Mar 2026
Crescent Biopharma, Inc. (NASDAQ: CBIO - Get Free Report) has been given an average rating of "Buy" by the nine brokerages that are currently covering the firm, MarketBeat.com reports. One research an
Crescent Biopharma Announces Grants of Inducement Awards
04:15pm, Friday, 06'th Mar 2026
WALTHAM, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing
Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
07:30am, Thursday, 26'th Feb 2026
Established partnership with Kelun-Biotech expanding pipeline and accelerating combination strategy with CR-001, PD-1 x VEGF bispecific antibody, and multiple ADCs
Crescent Biopharma to Present at March Investor Conferences
07:30am, Monday, 23'rd Feb 2026
WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing t
Crescent Biopharma Announces Grants of Inducement Awards
07:30am, Thursday, 19'th Feb 2026
WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing t
Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors
07:30am, Wednesday, 18'th Feb 2026
ASCEND to evaluate CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types, including NSCLC and gastrointestinal and gynecological cancers in first-line and previously treated patient
Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
07:30am, Thursday, 05'th Feb 2026
WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing t
